Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study.
Joachim SieperRobert LandewéMarina MagreyJaclyn K AndersonSheng ZhongXin WangApinya LertratanakulPublished in: RMD open (2019)
In ABILITY-3, consistent and strong baseline predictors of remission included younger age, male sex, HLA-B27 positivity and higher SPARCC MRI sacroiliac joint score among patients with active nr-axSpA receiving adalimumab therapy, similar to previous findings in ankylosing spondylitis.
Keyphrases
- ankylosing spondylitis
- disease activity
- rheumatoid arthritis
- juvenile idiopathic arthritis
- systemic lupus erythematosus
- open label
- ulcerative colitis
- magnetic resonance imaging
- clinical trial
- contrast enhanced
- randomized controlled trial
- squamous cell carcinoma
- stem cells
- computed tomography
- mesenchymal stem cells
- study protocol
- phase ii
- bone marrow